secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001628280-25-022753
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland Q1 revenue $11.7M (+38% YoY), net profit $1.3M; DMD Phase II positive, Vibativ China OK
--------------------------------------------------------------------------------

- Net revenue $11.7M vs $8.5M prior year, 38% increase.
- Net income $1.3M; adjusted earnings $2.4M ($0.16/shr); operating cash flow $3.9M.
- Positive Phase II data for ifetroban in Duchenne muscular dystrophy; FDA end-of-phase-II meeting planned.
- Vibativ approved in China; launch expected by end of 2025.
- Balance sheet: $15.1M cash, $5.2M drawn on credit facility; equity $28.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828025022753/0001628280-25-022753-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828025022753/cpix-20250506.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-022753

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer